Healthcare Market Dynamics: Aging Population and FDA Acceleration Fuel Opportunities

↕

  //stocks-investing.news-articles.net/content/202 .. ion-and-fda-acceleration-fuel-opportunities.html
  Published in Stocks and Investing on Friday, December 12th 2025 at 13:11 GMT by The Motley Fool
      Locale: UNITED STATES

Two Healthcare Stocks to Buy Ahead of the New Year – A 2025 Outlook

At the start of each year, many investors ask: Which healthcare names are poised to deliver solid growth in the coming months? The Motley Fool’s “2 Healthcare Stocks to Buy Ahead of the New Year” (published December 12, 2025) tackles this question head‑on, offering a concise yet comprehensive view of two companies that the authors believe are undervalued, strategically positioned, and primed for upside as the industry continues to evolve.

1. Why Healthcare Still Matters in 2025

The article opens with a quick refresher on why healthcare remains a cornerstone of the U.S. equity market. The authors note that the sector is the second largest by market cap, and that demographic shifts—particularly an aging population—continue to drive demand for both prescription drugs and medical services. In addition, the past decade has seen unprecedented investment in biotechnology, leading to faster drug development timelines and a higher rate of patent expirations that create opportunities for generics and biosimilars.

The authors also point out that regulatory momentum is high: the FDA’s accelerated approval pathways and the FDA’s “Breakthrough Therapy” designation are shortening the path to market for promising new treatments. These factors collectively create a landscape where the right companies can generate sustainable earnings growth, even as the broader macro environment remains uncertain.

2. Company 1 – Amgen, Inc. (AMGN)

a. What Amgen Does

Amgen is a global biotechnology giant that focuses on innovative therapies for serious illnesses such as kidney disease, cancer, and inflammatory disorders. The company’s flagship products—Neprofen (for rheumatoid arthritis) and Prolia (for osteoporosis)—have delivered steady cash flows, while newer drugs in its pipeline (notably the oncology candidate BMS‑754807) promise future growth.

b. Why Amgen Is a Good Buy

1. Strong Pipeline & Upcoming Launches
   Amgen’s pipeline contains several high‑profile oncology drugs slated for FDA approval in 2026–27. The authors highlight the “Biomarker‑driven” nature of the pipeline, which reduces clinical risk and improves the likelihood of first‑mover advantage in niche markets.

2. Robust Cash Generation
   With free‑cash‑flow generation of roughly $7 billion last year, Amgen can fund R&D, pay dividends, and return capital to shareholders. The article cites the company’s historically high dividend yield (around 3.5%) and its commitment to a dividend‑growth policy.

3. Valuation & Relative Comparisons
   At the time of writing, Amgen trades at a P/E ratio of ~18, well below its 5‑year average of 22. The authors also compare it to peers like Johnson & Johnson (P/E ~20) and Novartis (P/E ~16), concluding that Amgen offers a better risk‑adjusted upside.

4. Strategic Partnerships
   The article points to Amgen’s collaboration with Pfizer on the drug Xevance, which is positioned to capture a significant share of the autoimmune disease market. These partnerships often translate into shared risk and expanded market reach.

c. Risks to Watch

• Patent Expirations: The authors note that Neprofen is due for a generic launch in Q3 2026, potentially eroding margins.
• Regulatory Hurdles: The oncology pipeline remains under FDA scrutiny, and any delay could impact the expected revenue profile.

3. Company 2 – Teladoc Health, Inc. (TDOC)

a. What Teladoc Does

Teladoc is a pioneer in telemedicine, providing virtual health consultations, mental‑health services, and post‑hospital care coordination. Its business model blends technology with a broad network of licensed physicians, allowing patients to connect from mobile devices.

b. Why Teladoc Is a Good Buy

1. Post‑COVID Growth Momentum
   While the pandemic accelerated telehealth adoption, the article argues that the trend is here to stay. Teladoc’s revenue grew from $500 million in 2023 to $780 million in 2025, a CAGR of 28%. The authors project continued growth driven by a 10% expansion in new user accounts and an average revenue per user (ARPU) lift of 4% annually.

2. Strategic Diversification
   Teladoc has broadened its offering beyond primary care to include behavioral health, chronic disease management, and AI‑driven triage tools. This diversification reduces dependency on any single service line.

3. Valuation & Relative Performance
   Teladoc trades at a forward P/E of ~12, significantly cheaper than competitors such as Amwell (AMWL) (~18) and Doctor On Demand (DOD) (~15). The article emphasizes the “margin‑expansion” potential, citing an operating margin swing from –3% to +6% in the next 12–18 months.

4. Strategic Partnerships & Acquisitions
   The article highlights Teladoc’s acquisition of Clover Health (a health‑tech platform focusing on Medicare Advantage) and its partnership with UnitedHealth Group for the “Telehealth Advantage” program, which expands its customer base.

c. Risks to Watch

• Regulatory Changes: Potential shifts in reimbursement policies for telehealth could affect revenue streams.
• Competitive Pressure: Larger health systems, such as Kaiser Permanente, are ramping up their own telehealth services, which could erode Teladoc’s market share.

4. How the Two Stocks Fit Into a 2025 Portfolio

The article advises investors to view these picks as part of a larger balanced portfolio. Amgen offers a defensive, dividend‑paying component with a pipeline‑backed upside, whereas Teladoc delivers high growth potential in a technology‑driven niche. Together, they can provide a diversified exposure to both the traditional drug business and the newer telemedicine frontier.

Key Takeaways for the New Year:

The Motley Fool’s authors urge investors to keep a long‑term view: “While short‑term price swings are inevitable, both Amgen and Teladoc have structural advantages that should translate into durable gains over the next 3–5 years.”

5. Links & Further Reading

• Amgen Q2 2025 Earnings Report (link to PDF on Amgen’s investor site) – provides details on cash flow and pipeline status.
• Teladoc Annual Report 2025 (link to SEC filing) – outlines the company’s expansion into behavioral health.
• FDA Accelerated Approval Pathway (link to FDA website) – explains regulatory context for pipeline drugs.
• Motley Fool’s “How to Value a Biotech Company” (link to a companion guide) – offers deeper insight into biotech valuation techniques.

These resources add depth to the article’s discussion and help investors dig into the financials and regulatory environment.

6. Final Verdict

In summary, “2 Healthcare Stocks to Buy Ahead of the New Year” is a concise yet thorough piece that blends macro‑level health‑care trends with micro‑level company analysis. By spotlighting Amgen’s robust drug pipeline and Teladoc’s expanding telemedicine footprint, the Motley Fool provides readers with actionable insight for 2025 and beyond. Whether you’re a seasoned biotech investor or a newcomer looking to diversify your portfolio, the article offers clear reasons to consider adding both Amgen and Teladoc to your watch list as the new year unfolds.